We recently published a list of 10 Stocks Insiders Are Buying This Year. In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other stocks that insiders are buying this year.
Even though this is just the beginning of the year, we thought it might be interesting to see what stocks have attracted the most attention from insiders. Why? Sometimes, when executives or insiders acquire shares early in the year, it could mean that they expect strong financial results or positive company developments.
On the other hand, insiders sometimes sell shares at the beginning of the year for tax reasons. For example, they can sell shares to harvest tax loss or to balance out gains/losses from the previous year.
Both insider selling and buying can be driven by various motives, however, it’s important to consider these moves within the broader context of the company’s fundamentals, industry trends, and overall market conditions. That’s why due diligence before any investment is of the utmost importance. However, insider trading activity in combination with other relevant determinants can offer valuable insights into a company’s capabilities, helping investors make more informed investment decisions.
To identify the 10 stocks insiders are buying this year we used Insider Monkey’s insider trading stock screener and looked for stocks with at least five insiders buying since the beginning of the year. With each stock, we note the number of insiders who recently bought shares.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Copyright: dolgachov / 123RF Stock Photo
Sionna Therapeutics, Inc. (NASDAQ:SION)
Number of Insiders Buying: 6
Sionna Therapeutics, Inc. (NASDAQ:SION) is a biopharmaceutical company developing treatments for cystic fibrosis (CF). The company is focused on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Its goal is to create various medicines for people with CF that will restore CFTR function to nearly normal.
The company’s co-founders have more than a decade of research in this area, so Sionna (NASDAQ:SION) is working on advancing a pipeline of small molecules engineered to correct the defects caused by the most common CF genetic mutation.
On February 10th, six insiders acquired $62.46 million worth of Sionna shares at a price of $18 per share. Insiders took part in the company’s upsized initial public offering, via which it raised $219.2 million. Sionna (NASDAQ:SION) said it plans to use raised capital to advance its CF drug development programs.
Director Peter A. Thompson showed confidence in the company’s future by buying 550,000 shares, worth $9.9 million. With this move, Thompson raised his holding to 3.70 million Sionna’s shares.
Since this is a stock that recently went public, there’s not much analyst coverage yet, and also no public finance reports.
The stock is currently trading at $20.03, and its market cap is $849.29 million.
Overall, SION ranks 9th on our list of stocks that insiders are buying this year. While we acknowledge the potential of SION, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SION but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.